Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Reference: Relacorilant with nab-Paclitaxel for Platinum-Resistant Ovarian Cancer
In this phase 3 trial of patients with platinum-resistant ovarian cancer, relacorilant combined with nab-paclitaxel significantly improved overall survival by extending median surv
New Protocol: Pembrolizumab and Paclitaxel for Recurrent Ovarian Cancer
This phase 3 study showed that adding pembrolizumab to weekly paclitaxel, with or without bevacizumab, significantly improved progression-free survival and overall survival in pati
New Reference: Lenvatinib with Pembrolizumab in Head and Neck Cancer
This phase III study evaluated lenvatinib plus pembrolizumab versus placebo plus pembrolizumab in patients with PD-L1 positive recurrent or metastatic head and neck squamous cell c
New Reference: Lenalidomide-Rituximab for Indolent Non-Hodgkin Lymphoma
In the phase III AUGMENT trial with 5-year follow-up, lenalidomide plus rituximab significantly improved progression-free survival compared with rituximab plus placebo in patients
New Drug: Gedatolisib for ER+ Advanced Breast Cancer
This phase III randomized trial demonstrated that adding gedatolisib to fulvestrant, with or without palbociclib, significantly improved progression-free survival compared to fulve
New Drug: Daraxonrasib for kRAS Mutated Pancreatic Cancer
In this phase 1-2 study involving patients with previously treated RAS-mutated pancreatic ductal adenocarcinoma, daraxonrasib administered at up to 300 mg daily demonstrated antitu
New Reference: SubQ Daratumumab with VCd for Newly Diagnosed Amyloidosis
In this phase 3 trial of newly diagnosed AL amyloidosis, adding subcutaneous daratumumab to VCd significantly improved hematologic complete response rate. The combination also impr
New Reference: Tucatinib for Leptomeningeal Metastasis
This phase 2 study in patients with HER2-positive breast cancer and leptomeningeal metastases showed that tucatinib, trastuzumab, and capecitabine achieved a median overall surviva
New Protocol: Trabectedin Olaparib Combo for Soft Tissue Sarcoma
This phase II randomized study in advanced soft tissue sarcoma patients found a marginal progression-free survival benefit with trabectedin plus olaparib compared to trabectedin al
